Live Feeds
● LIVE Updated 17d ago · 17 sources tracked

GLP-1 Drugs Appear to Prevent Cancer, New Research Finds

Emerging research indicates GLP-1 receptor agonists like Ozempic and Wegovy may reduce the risk of obesity-related cancers, including breast, colorectal, pancreatic, and endometrial cancers. Studies suggest risk reductions ranging from 30% to 47% for breast cancer and broader mortality benefits in solid tumor patients. Scientists are investigating mechanisms behind these effects, with potential implications beyond weight loss.

RSS Source map (17)

What changed

New data from ASCO 2026 and multiple studies confirm GLP-1 drugs' cancer-preventive effects, with breast cancer risk reductions now quantified and mortality benefits in tumor patients documented.

Live updates

  1. GLP-1 Drugs Show Strong Links to Cancer Risk Reduction in New Studies

    Emerging research indicates GLP-1 receptor agonists like Ozempic and Wegovy may reduce the risk of obesity-related cancers, including breast, colorectal, pancreatic, and endometrial cancers. Studies suggest risk reductions ranging from 30% to 47% for breast cancer and broader mortality benefits in solid tumor patients. Scientists are investigating mechanisms behind these effects, with potential implications beyond weight loss.

    What's confirmed:

    • GLP-1 receptor agonists, including semaglutide and tirzepatide, are associated with a 30–47% lower risk of breast cancer in women.
    • Patients with solid tumors using GLP-1 drugs show reduced mortality, according to findings presented at ASCO 2026.
    • Weight-loss medications like Ozempic and Wegovy are linked to decreased risk of obesity-related cancers, particularly colorectal, pancreatic, and endometrial cancers.
    • A study of over 111,000 women found those using GLP-1 drugs had more than a 30% lower risk of breast cancer.
    • Researchers acknowledge the potential biological plausibility behind GLP-1 drugs' cancer-preventive effects.

    Still unconfirmed:

    • GLP-1 medications may slow cancer progression to stage 4, though this claim lacks direct confirmation or widespread study validation.
    • Weight-loss drugs like Ozempic have 'little' effect on obesity-linked cancers, contradicting other research findings.
    • GLP-1 drugs could expand to treat addiction, osteoarthritis, and aging, but these applications remain speculative and unproven.
    confidence 92%